IBD
Risankizumab resolves extraintestinal manifestations in CD
DIVERSITY1: Filgotinib results leave investigators puzzled
Obefazimod takes the spotlight as promising UC treatment
Rapid response to upadacitinib boosts outcomes in severe Crohn’s disease
SEQUENCE: Risankizumab doubles endoscopic remission rates compared with ustekinumab in CD
LUCENT trials: Mirikizumab works in UC, regardless of targeted therapy history
Subcutaneous infliximab shows promise in UK IBD study
Guselkumab provides benefits in UC regardless of advanced therapy history
INSPIRE: Risankizumab meets all efficacy endpoints in UC
ARTEMIS-UC: New kid in town for UC
Linking the Black Death with Crohn’s disease predisposition
EVOLVE Expansion study: vedolizumab and ustekinumab as first-line biologic treatments for Crohn’s disease
Environmental and dietary factors can amplify paediatric IBD risk
Ulcerative colitis: bowel urgency remission associated with improvement in fatigue
Crohn’s disease: Upadacitinib improves endoscopic outcomes in participants with or without previous biologic failure
Checking kidney function is important during the course of IBD
Diabetes therapy with GLP-1-based drugs does not elevate the risk of IBD
Long-term resection potentially better than anti-TNF treatment in CD
Early, post-operative complications in CD reduced by pre-operative enteral nutrition, irrespective of biologic exposure
Perinatal period is crucial for the risk of developing CD
Drop in overall IBD procedures during the pandemic
Early-life antibiotic exposure: a risk factor for paediatric-onset IBD
Proton pump inhibitors associated with worse outcomes in CD
Paediatric patients with immune-mediated inflammatory disease harbour a heightened cancer risk
Poor sleep in CD linked to low levels of vitamin D
Long-term data supports the established efficacy and safety of ustekinumab in UC
Anti-TNF withdrawal may be a safe option in stable IBD
Solid results for long-term therapy of UC with filgotinib
Fast recapture of response with ozanimod after withdrawal in UC
Ozanimod treatment prompted substantial response after failure of response to induction
Etrasimod shows advantage over placebo in UC
Etrasimod reduces adaptive immune cells in the periphery in UC
Favourable maintenance rates for risankizumab also in delayed responders with CD
IL-23 inhibition reduces inflammatory biomarkers in pre-treated UC
Maintained symptom control with mirikizumab in UC
Mirikizumab successfully resolves active histologic inflammation in UC
Upadacitinib for CD: remarkable efficacy in induction therapy
Sustained maintenance results with upadacitinib in UC
Start low with brepocitinib and ritlecitinib in UC
Another chance for TYK2 inhibition in UC
Small molecule obefazimod shows promise in UC
Pivotal results of etrolizumab for CD partly disappointing
Better results for vedolizumab in early CD
Some patients with limited CD may benefit from an early surgical intervention
Dose-interval of adalimumab might be prolonged in CD patients in stable remission
High prevalence of fibromyalgia in patients with inflammatory bowel disease
Antibiotic use elevates IBD risks in senior citizens
Too much hygiene: CD in later life?
Biologic treatment decreases dementia risk in senior IBD patients
CD: Induction treatment with upadacitinib successful in clinical and endoscopic ratings
IL-23 inhibition beneficial in maintenance treatment of UC
Positive outcomes for etrasimod in UC
Colonoscopy in UC: less pain and reduced recurrence with CO2 insufflation
Lessons from the COVID-19 pandemic for IBD management
AI model distinguishes between histologic activity and remission in ulcerative colitis
Multi-Omic and dietary analysis of Crohn’s disease identifies pathogenetic factors
Novel classification system for perianal fistulising Crohn’s disease
Vaccination tool associated with improved vaccination coverage in IBD
Comparable safety profiles of biological therapies in elderly patients with IBD
Early biologic therapy induces larger effect than delayed treatment in Crohn’s disease
RESTORE-UC: No better outcomes with FMT superdonors than with autologous stools
Segmental colectomy beneficial over total colectomy in Chrohn’s disease
Similar results for different corticosteroid tapering protocols in UC
Ozanimod treatment shows maintained response in ulcerative colitis
Stopping infliximab but not antimetabolites leads to more relapses in Crohn’s disease
Vedolizumab first approved therapy for chronic pouchitis
VEDOKIDS: Vedolizumab seems effective in paediatric IBD
Primary endpoint of 5-hydroxytryptophan for fatigue in IBD not met
Anti-TNFs versus vedolizumab and ustekinumab in Crohn’s disease
Upadacitinib appears to be an efficacious therapy for moderately-to-severely ulcerative colitis
Subcutaneous infliximab versus subcutaneous vedolizumab in IBD
Vedolizumab outperforms anti-TNF in biologic-naïve ulcerative colitis
Guselkumab shows encouraging safety and efficacy in ulcerative colitis
Guselkumab maintenance therapy achieved high efficacy rates in Crohn’s disease
Mirikizumab efficacious for active ulcerative colitis
Risankizumab more efficacious in colonic than in ileal Crohn’s disease
Guselkumab plus golimumab promising combination for ulcerative colitis
Combined endpoint may support personalised medicine in ulcerative colitis
Filgotinib seems promising for perianal fistulising Crohn’s disease
Upadacitinib maintenance therapy delivers sustained improvements in active ulcerative colitis
Upadacitinib counters extraintestinal manifestations in ulcerative colitis
Upadacitinib effector pathways unravelled
Deucravacitinib does not meet primary endpoint for ulcerative colitis
Women with IBD expect their gastroenterologist to initiate discussion of reproductive health
Crohn’s strictures may respond to immunosuppressive drug therapy
Simple scoring system may safely reduce abdominopelvic CT in Crohn’s patients
Antibiotics plus oral fecal microbiota transplantation tied to ulcerative colitis remission
Etrolizumab down but not out for ulcerative colitis: studies
Crohn’s disease exclusion diet may produce remission of mild-to-moderate disease
Anti-TNF therapy tied to better outcomes in IBD patients with COVID-19
Assisted reproductive therapy safe in women with IBD, but efficacy mixed
Risankizumab meets primary endpoints in maintenance study for CD patients
Ustekinumab treat-to-target strategy offers long-term alternative for standard-of-care in CD
Upadacitinib efficacious and safe as maintenance therapy for UC
Upadacitinib outperforms placebo in UC patients with inadequate response to biologics
Rapid symptom control for UC patients on upadacitinib
Filgotinib demonstrates promising results for various lines of therapy in UC
Filgotinib demonstrates long-term corticosteroid-sparing effects in UC
Long-term benefits of tofacitinib for substantial proportion of UC patients
Ritlecitinib and brepocitinib are promising JAK inhibitors for UC
Serologic response to COVID-19 mRNA vaccine reduced in IBD patients on anti-TNFα
Serious adverse events put a stop to ASTIClite trial for CD
Home infusion safe for IBD patients receiving infliximab and vedolizumab
UEGW 2021 Highlights Podcast
Rectal compliance lower than normal in ulcerative colitis, but recovery is possible
Live varicella-zoster vaccine safe, effective with TNF inhibitors
Could steroid treatment speed recovery from infliximab-induced liver injury?
Subcutaneous vedolizumab appears effective maintenance therapy in Crohn’s disease
Adalimumab biosimilar on par with original in Crohn’s disease
New target to dial down inflammation and pain discovered
TAVI safe and effective in patients with inflammatory bowel disease
Pfizer-BioNTech vaccine effectiveness comparable in IBD patients, general population
Adalimumab safe and effective in children with ulcerative colitis
No increased risk of (severe) COVID-19 among IBD patients
Blood proteins predicting relapse in CD identified
Similar efficacy of ustekinumab and adalimumab for moderate-to-severe CD
Upadacitinib meets primary endpoint for moderate-to-severe UC
Oral faecal microbiota transplant therapy efficacious in UC
Extracellular RNA has potential as a non-invasive biomarker in IBD
Ustekinumab safe and effective in elderly CD patients
Promising safety and pharmacokinetic data on BT051 for UC
Artificial intelligence outperforms human classifying of endoscopic images in UC
Early clinical remission and response following risankizumab therapy in CD
Surgical closure plus anti-TNF outperforms anti-TNF alone for perianal fistula
Increased risk of rectal cancer after colectomy in IBD
Risk of hospitalisation and surgery linked to IBD biological
Risk of colorectal cancer is detected by low-pass whole genome sequencing
Large variability in IBD care and education across Europe
Ultra-processed food intake associated with IBD
Factors of coping difficulties in IBD revealed
Obesity increases the risk of immunogenicity to adalimumab in IBD
Contrast-free imaging can spot post-op Crohn’s recurrence
Specific carbohydrate diet not superior to Mediterranean diet for Crohn’s disease
Stopping infliximab linked to relapse in ulcerative colitis
mRNA COVID-19 vaccines effective in IBD patients receiving biological therapies
IBD patients should be screened for anxiety, depression
PICaSSO tool promising for predicting histologic remission in ulcerative colitis
Ustekinumab works well in ulcerative colitis in the general population
Reassuring data on immune checkpoint inhibitors in autoimmune disease
Adherent-invasive E. coli metabolism drives inflammation in Crohn’s disease
Hirschsprung disease tied to increased risk of inflammatory bowel disease
IBD patients with clinical remission often malnourished, sarcopenic
IV ferric carboxymaltose tops IV iron sucrose for iron-deficiency anemia in IBD
Cigarette smoke tied to colorectal neoplasia in IBD patients
Promising longer-term data for etrasimod in ulcerative colitis
Anti-cytokine therapy normalizes ACE2 expression in IBD, may protect against COVID-19
Race, ethnicity affect epidemiology and management of inflammatory bowel diseases
Sustained efficacy of mirikizumab in moderate-to-severe Crohn’s disease
No improvements of remission with etrolizumab in ulcerative colitis
Filgotinib effective as maintenance treatment for ulcerative colitis
Post-colonoscopy colorectal cancers in IBD patients
Risk factors for severe COVID-19 among IBD patients
First randomised T2T trial using endoscopy to guide dose escalation
Cobitolimod might induce remission in moderate-to-severe left-sided ulcerative colitis
Bioenhanced curcumin may induce remission in ulcerative colitis
IBS symptoms common in patients with IBD in remission
Resolution of mucosal inflammation has dramatic effect
Re-inducing inflammation in organoids from UC patients
Role of immune cells in intestinal fibrosis
Association between meat consumption and IBD risk
Increased risk of small bowel cancer in IBD
Effects of vedolizumab versus adalimumab on QoL
On the cutting edge of pathology and surgery
Impact of strategies on intestinal resection rate
Early ileocaecal resection in CD patients failing conventional treatment
Ustekinumab in CD: a T2T trial
Subcutaneous ustekinumab as maintenance therapy in UC
Subcutaneous vedolizumab maintenance therapy in CD
Vedolizumab treatment persistence and safety
Pipeline of IBD drugs
Phase 2 results of first-in-class TL1A inhibitor
Open-label extension study of risankizumab: final results
Clinical remission after dose escalation of upadacitinib
Response to faecal microbiota transplantation in UC
Multi-omics help describe CD phenotypes
The positive impact of genetic data on drug development
Bioactives produced by gut bacteria to modulate immune response
Ustekinumab is safe and effective in ulcerative colitis: 2-year data
Ileal microbiota predict recurrence in CD patients after resection
Decreased microvilli length in CD patients
Phase 2 data shows benefit for mirikizumab in CD patients
Subcutaneous ustekinumab as maintenance therapy in UC
Global burden of digestive diseases reveals alarming trends
First evidence of long-term efficacy of ABX464 in ulcerative colitis
New treatment may reverse coeliac disease
IBD prevalence 3 times higher than estimated and expected to rise
Haematopoietic stem cells can sense tissue damage in the gut
The right drug for the right patient
Vedolizumab superior to adalimumab in ulcerative colitis
Crohn’s disease exclusion diet + partial enteral nutrition in paediatric Crohn’s disease
The costs and benefits of biologicals
Selective sphingosine-1-phosphate receptor modulator etrasimod
Ustekinumab as maintenance therapy and with shortened interval
Early remission of Crohn’s disease prevents progression
Microbial composition and psychological wellbeing
Immune cells and microbes: a happy marriage?
Gene expression signature predicts non-response
IBD risk of treatment with IL-17 antagonists
Proactive adalimumab trough measurements
Vedolizumab induces endoscopic remission and healing in refractory CD
